Follytropyn beta | Puregon solution for p / dermal introduction. 300 IU cartridge 0.36 ml per set with needles 6 pcs. 1 pack

Packaging

1 cartridge

Pharmacological action

Puregon - follicle-stimulating. Puregon makes up for FSH deficiency. Regulates the normal growth and maturation of follicles, the synthesis of sex steroid hormones.

Indications

Female infertility during anovulation (including polycystic ovary syndrome, refractory to clomiphene citrate) assisted reproduction programs, including in vitro fertilization (for the induction of superovulation).

Contraindications

Hypersensitivity, tumors of the ovaries, breast, uterus, pituitary or hypothalamus, primary ovarian failure, ovarian cysts or ovarian enlargement not associated with polycystic ovary syndrome, violation of the anatomy of the genital organs or uterine fibroma, incompatible with pregnancy.

Use during pregnancy and lactation

Contraindicated in pregnancy. Lactating women should abandon breastfeeding.

Composition

1 cartridge contains:

Active ingredient: follitropina-beta 300 IU.

Side effects

Ovarian hyperstimulation (abdominal pain, nausea, diarrhea, enlarged ovaries and their cysts, rarely - rupture of ovarian cysts, ascites, hydrothorax, weight gain) at the injection site - edema, pain, redness, itching. After the induction of ovulation, the risk of developing multiple pregnancy is increased, and with in vitro fertilization - an ectopic pregnancy.

Drug Interaction

Concomitant administration of Puregon and clomiphene may enhance ovarian response.

A higher dose of Puregon may be required after pituitary desensitization with GnRH agonists to achieve sufficient ovarian response.

Pharmaceutically incompatible with other medicines.

overdose

There is no evidence of an acute overdose of the Puregon drug. The use of FSH at high doses can lead to the development of ovarian hyperstimulation syndrome, the symptoms of which are described above.

Treatment: In the event of symptoms of unwanted hyperstimulation (not related to the induction of superovulation during in vitro fertilization), the administration of Puregon should be discontinued. In this case, measures should be taken to prevent pregnancy and to refuse the introduction of HG, which may aggravate the undesirable effects. Treatment should be performed to eliminate the symptoms of ovarian hyperstimulation syndrome.

Storage conditions

In a dark place at a temperature of 2–8 РC (do not freeze).

Expiration

2 Year

Deystvuyuschee substances

Follytropyn beta

dosage form

dosage form

injection